SURVYR

AARD

Aardvark Therapeutics, Inc.
$1.51
+$0.21 (16.15%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-91%-58%-24%+9%+42%Oct 2025Oct 2026Apr 202652w high $16.6052w low $3.35
AARDSPY
Wall St. Highest PT $28.00 (+1754.3%) Wall St. Avg PT $10.89 (+621.1%)
$1$10$20$29$38POC $6Hi $28Avg $11
Underwater Drawdown %Max DD -93.2%Current -90.5%
0.0%-93.2%
Relative Strength vs SPY-101.0% vs SPYUnderperforming
+119%0%-119%
1W
−$2.90 (65.76%)
1M
−$3.76 (71.35%)
3M
−$3.81 (71.62%)
6M
−$3.70 (71.02%)
YTD
−$11.61 (88.50%)
1Y
−$10.49 (87.42%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
11 analysts · mean score 2.18
1 = Strong Buy · 5 = Sell
Strong Buy655%
Buy00%
Hold327%
Underperform19%
Sell19%
Wall Street consensus · as of Oct 19, 2026
Analyst price targets
Current price$1.51
Average target$10.89
+$9.38 (+621.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$3.00
Median$6.00
High$28.00
12-month Wall Street target range · as of Oct 19, 2026
Recent analyst rating changes · 30
Reiterated
2026-10-19 · HC Wainwright & Co. reiterated Neutral on AARD
Reiterated
2026-09-24 · RBC Capital reiterated Sector Perform on AARD
Reiterated
2026-07-20 · HC Wainwright & Co. reiterated Neutral on AARD
Reiterated
2026-05-15 · B. Riley Securities reiterated Buy on AARD
Downgrade
2026-05-15 · BTIG downgraded AARD from Buy to Neutral
Downgrade
2026-05-15 · Morgan Stanley downgraded AARD from Equal-Weight to Underweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$86.4M
P/E (next 12 months, estimated)-1.7
52-week range$3.35 – $16.60
Dividend yieldNo dividend
Analyst consensusBuy (9)
Average analyst price target$10.89 (+621%)

What they do

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AARD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AARD earningsNext report in 15 days
Next report
Thu Nov 12, 2026Time not confirmed
EPS consensus-$0.70 range -$1.07–-$0.55
Revenue consensus$0 8 analysts
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.66est -$0.88+25.1%Above estimates
May 7, 2026-$0.99est -$0.91−8.9%Below estimates
Mar 23, 2026-$0.81est -$0.83+2.1%Above estimates
Nov 13, 2025-$0.75est -$0.82+8.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-22 20:44:25 ET
25-0325-0525-0825-1126-0326-0526-08-2.180.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Aardvark Therapeutics stock surges as FDA lifts clinical hold
Investing.com · Oct 22
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
GlobeNewswire · Oct 22
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Zacks · Oct 21
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
PR Newswire · Oct 12
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
GlobeNewswire · Oct 08
Rating changes
Reiterated
2026-10-19 · HC Wainwright & Co. reiterated Neutral on AARD
Reiterated
2026-09-24 · RBC Capital reiterated Sector Perform on AARD
Reiterated
2026-07-20 · HC Wainwright & Co. reiterated Neutral on AARD
Reiterated
2026-05-15 · B. Riley Securities reiterated Buy on AARD
Downgrade
2026-05-15 · BTIG downgraded AARD from Buy to Neutral
Downgrade
2026-05-15 · Morgan Stanley downgraded AARD from Equal-Weight to Underweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Sun Nelson
See Remarks · 2026-09-11
Sell
$321.2K
Sun Nelson
See Remarks · 2026-09-10
Sell
$73.8K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-22 20:44:25 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026